Research Paper Undergraduate 1,626 words

Chronic Myelogenous Leukemia: Causes, Stages, and Treatments

~9 min read 6 sections Medicine · Chemotherapy

Abstract

This paper provides a comprehensive overview of chronic myelogenous leukemia (CML), a progressive blood cancer driven by the BCR-ABL fusion protein produced by the Philadelphia chromosome translocation. It covers CML's etiology, epidemiology, pathophysiology, disease staging, and the full range of treatment options available to patients. Topics include traditional chemotherapy, the landmark development of imatinib and subsequent kinase inhibitors, biologic and immunotherapy approaches, and allogeneic hematopoietic stem cell transplantation. The paper also addresses kinase inhibitor resistance and the emerging role of the immune system — particularly natural killer cells — in achieving long-term remission or potential cure.

Key Takeaways

Introduction: CML overview and cellular biology basics
CML Etiology: Philadelphia chromosome, BCR-ABL fusion protein origins
CML Epidemiology: Prevalence, demographics, and survival statistics
CML Pathophysiology and Disease Staging: Symptoms, diagnosis, and three disease phases
Treatments and Medications: Chemotherapy, kinase inhibitors, biologics, transplantation
Summary: Future immunotherapy outlook and prognosis

✍️ How to write this paper — guide, tools & examples ▾

What makes this paper effective

The paper moves logically from disease biology (etiology, epidemiology, pathophysiology) to clinical application (treatments), giving readers the context needed to understand why each therapy works or fails.
Specific clinical data — such as MCyR rates, CCyR percentages, and eight-year follow-up statistics from the imatinib trial — ground abstract claims in concrete evidence.
The paper acknowledges treatment limitations (kinase inhibitor resistance, indefinite drug dependence) and connects them to emerging therapies, demonstrating critical thinking beyond a simple literature summary.

Key academic technique demonstrated

The paper exemplifies evidence-based synthesis: rather than simply describing each treatment in isolation, it traces the historical progression of CML therapy — from early chemotherapy to interferon augmentation to kinase inhibitors to immunotherapy — showing how each advance addressed the limitations of the previous approach. This chronological-within-thematic structure is a strong model for medical and science writing.

Structure breakdown

The paper opens with an abstract-style preamble, then proceeds through six clearly delineated sections: an introduction establishing CML's cellular basis; an etiology section explaining the Philadelphia chromosome and BCR-ABL fusion protein; an epidemiology section with prevalence and survival statistics; a pathophysiology section detailing symptoms, diagnosis, and the three disease phases; a treatment section covering chemotherapy, kinase inhibitors, biologics, and donor lymphocyte infusion; and a brief forward-looking summary. The reference list follows APA format.

📘 Read the full research paper guide → Generate citations → Build an outline → Draft a literature review → 📚 More Chemotherapy examples →

Essay 1,626 words

Introduction

Patients suffering from chronic myelogenous leukemia (CML) experience recurrent infections, anemia, and thrombocytopenia — signs and symptoms that are often manageable without professional help. Accordingly, patients often failed to seek medical care until late in the disease course and would have faced a poor prognosis in the 20th century. Today, a number of effective treatments are available, including the highly effective kinase inhibitor imatinib. Kinase inhibitors suppress the activity of the fusion protein p210^BCR-ABL, which is the product of a chromosomal translocation between chromosomes 9 and 22. Over half of all CML patients become symptom-free with the use of kinase inhibitors and live long, productive lives, but a smaller percentage require more aggressive and riskier treatment approaches, among which is allogeneic hematopoietic stem cell transplantation following high-dose chemotherapy.

Chronic myelogenous leukemia (CML) is a progressive disease that impairs the normal function of blood cells (National Cancer Institute, 2015a). The bone marrow in a healthy person contains hematopoietic stem cells from which blood cells develop. The two primary lineages derived from hematopoietic stem cells are myeloid and lymphoid, with the lymphoid lineage generating a number of critical immune cells. The terminal lymphoid cell types are B lymphocytes, T lymphocytes, and natural killer cells. By contrast, the myeloid precursor can differentiate into red blood cells, platelets, eosinophils, basophils, and neutrophils. The latter three cell types are collectively called granulocytes (blasts) and are also critical for immune function. In patients with CML, granulocytes proliferate and overpopulate the bone marrow and circulatory compartments, leading to impaired functioning of other myeloid and lymphoid cell types. The result is recurrent infections, anemia, and thrombocytopenia (bleeding problems), due to impaired immunity, red blood cell function, and platelet activity, respectively.

CML Etiology

The most common cause of CML is a translocation between chromosomes 9 and 22 in a bone marrow stem cell or myeloid precursor (National Cancer Institute, 2015a). The resulting chromosome 22 is called the Philadelphia (Ph) chromosome. The translocation brings a portion of the Abelson proto-oncogene ABL — a non-receptor tyrosine kinase — next to the BCR gene, such that two new genes are created on chromosomes 9 and 22: BCR-ABL on chromosome 22 and ABL-BCR on chromosome 9 (Levitan et al., 2003). Most research has focused on the activity of the BCR-ABL gene product, p210^BCR-ABL, which is a 210 kDa cytoplasmic fusion protein with constitutive tyrosine kinase activity. The p210^BCR-ABL kinase in turn induces dysregulated proliferation of granulocytes.

CML Epidemiology

CML is the rarest of the four major types of leukemia in the United States, with a prevalence estimated at 33,990 in 2011 (Leukemia & Lymphoma Society, 2015). In 2014, an estimated 5,980 new cases of CML were diagnosed, representing 11.4% of all leukemia cases. Other estimates suggest the prevalence is much higher, with 160,000 individuals suffering from CML in the United States in 2014 (Sweet, Pinilla-Ibarz, & Zhang, 2014). Although individuals of any age can develop CML, only 3.1% of cases occur in individuals under 20 years of age (Leukemia & Lymphoma Society, 2015). Men are slightly more at risk, representing 52% of all cases, while the risk for all types of leukemia is highest among non-Hispanic Whites. The five-year survival rate for CML was 59.9%, compared to 25.4% for acute myeloid leukemia, 70% for acute lymphoblastic leukemia, and 83.5% for chronic lymphocytic leukemia. In 2014, an estimated 810 Americans with CML died from the disease.

3 Sections Hidden · 765 words

CML Pathophysiology and Disease Staging210 words

Individuals often fail to recognize that they are suffering from CML, sometimes for months or even years (Mayo Clinic Staff, 2014). Unfortunately, the later the disease is diagnosed and treated, the poorer…

Treatments and Medications480 words

A standard CML treatment option is chemotherapy, which seeks to kill cancer cells systemically or regionally through the administration of cytotoxic drugs. The use of chemotherapy to treat CML predates the use of…

Summary75 words

With the development of kinase inhibitors, most CML patients can live normal lives and a few may be effectively cured. A smaller percentage of patients, especially those with kinase inhibitor resistance,…

View Full Document

References

Leukemia & Lymphoma Society. (2015). Someday is today: Facts 2014–2015. Retrieved from https://www.lls.org/content/nationalcontent/resourcecenter/freeeducationmaterials/generalcancer/pdf/facts.pdf.

Levitan, D. A., Nanda, R., Rowley, J. D., & Olopade, O. I. (2003). Myeloproliferative disorders. In D. W. Kufe, R. E. Pollock, R. R. Weichselbaum et al. (Eds.), Holland-Frei cancer medicine (6th ed.). Hamilton, Ontario: BC Decker. Retrieved from http://www.ncbi.nlm.nih.gov/books/NBK12465/.

Llander, M., Hekim, C., & Mustjoki, S. (2014). Immunology and immunotherapy of chronic myeloid leukemia. Current Hematologic Malignancy Reports, 9(1), 17–23.

Mayo Clinic Staff. (2014). Diseases and conditions: Chronic myelogenous leukemia. Retrieved from mayoclinic.org.

National Cancer Institute. (2015a). Chronic myelogenous leukemia treatment (PDQ): General information about chronic myelogenous leukemia. National Cancer Institute. Retrieved from http://www.cancer.gov/cancertopics/pdq/treatment/CML/Patient/page1.

National Cancer Institute. (2015b). Chronic myelogenous leukemia treatment (PDQ): Treatment option overview. National Cancer Institute. Retrieved from http://www.cancer.gov/cancertopics/pdq/treatment/CML/Patient/page4.

Santos, F. P., Kantarjan, H., Quintas-Cardama, A., & Cortes, J. (2011). Evolution of therapies for chronic myelogenous leukemia. Cancer Journal, 17(6), 465–476.

Sweet, K., Pinilla-Ibarz, J., & Zhang, L. (2014). Clinical advances in the management of chronic myelogenous leukemia: Focus on bosutinib and patient considerations. Patient Preferences and Adherence, 8, 981–986.

Key Concepts in This Paper

BCR-ABL Fusion Protein Philadelphia Chromosome Kinase Inhibitors Imatinib Cytogenetic Remission Hematopoietic Stem Cell Transplant Granulocyte Proliferation Donor Lymphocyte Infusion CML Disease Phases Immunotherapy